Increased risk and severity of unprovoked venous thromboembolism with clustering cardiovascular risk factors for atherosclerosis: Results of the REMOTEV registry

Gærtner, S.; Cordeanu, Elena-Mihaela; Mirea, C.; Frantz, A.-S.; Auger, Cyril; Ohlmann, Patrick; Schini‐Kerth, Valérie B.; Stephan, Dominique

doi:10.1016/j.ijcard.2017.11.055

Cited by 14 publications

(17 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…14 Important risk factors for arterial thromboembolism such as hypertension and diabetes are also risk factors for VTE, but their significance is far less prominent. 15 For patients with cancer, an externally validated clinical prediction model incorporating D dimer and only one clinical factor (tumour site category) has been shown to predict the risk of VTE. 16 2.…”

Section: Risk Factorsmentioning

confidence: 99%

See 1 more Smart Citation

Editor's Choice – European Society for Vascular Surgery (ESVS) 2021 Clinical Practice Guidelines on the Management of Venous Thrombosis

Kakkos

Gohel²,

Bækgaard

et al. 2021

European Journal of Vascular and Endovascular Surgery

397

323

View full text Add to dashboard Cite

Section: Risk Factorsmentioning

confidence: 99%

“…7. 15. How was this information developed and what do I need to know before reading the full document?…”

Section: What Are the Areas That Need Further Research?mentioning

confidence: 99%

Editor's Choice – European Society for Vascular Surgery (ESVS) 2021 Clinical Practice Guidelines on the Management of Venous Thrombosis

Kakkos

Gohel²,

Bækgaard

et al. 2021

European Journal of Vascular and Endovascular Surgery

397

323

View full text Add to dashboard Cite

“…REMOTEV is an ongoing observational, prospective registry enrolling all consecutive patients hospitalized in the Vascular Medicine Unit of Strasbourg University Hospital for acute DVT and/or PE [15,16,17,18,19]. In the present study, we analyzed the clinical characteristics, comorbidities, treatment, and events during the first 3 months after VTE diagnosis in PE patients.…”

Section: Methodsmentioning

confidence: 99%

“…For patients whose body weight was unknown, the estimated glomerular filtration rate (eGFR) was calculated using the abbreviated Modification of Diet in Renal Disease (MDRD) equation. VTE was classified as provoked or unprovoked depending on the presence or absence of the following associated risk factors: recent surgery (<3 months), prolonged immobilization (more than 3 days), recent travel (for more than 6 h) occurring within 1 month before VTE, known active cancer, pregnancy or a postpartum setting, and estrogen therapy (oral contraception or hormone replacement therapy) [18]. Known active cancer was defined as a recently diagnosed cancer (<6 months), cancer under treatment, or metastatic cancer.…”

Section: Methodsmentioning

confidence: 99%

Pulmonary Embolism and Coexisting Deep Vein Thrombosis: A Detrimental Association?

Cordeanu

Lambach

Heitz

et al. 2019

JCM

View full text Add to dashboard Cite

Background: The prognostic significance of coexisting deep vein thrombosis (DVT) in acute pulmonary embolism (PE) is controversial. This study aimed to provide routine patient care data on the impact of this association on PE severity and 3-month outcomes in a population presenting with symptomatic venous thromboembolism (VTE) from the REMOTEV registry. Methods and Results: REMOTEV is a prospective, non-interventional study of patients with acute symptomatic VTE, treated with direct oral anticoagulants (DOACs) or standard anticoagulation (vitamin K antagonists (VKA) or parenteral heparin/fondaparinux alone) for at least 3 months. From 1 November 2013 to 28 February 2018, among 1241 consecutive patients included, 1192 had a follow-up of at least 3 months and, among them, 1037 had PE with (727) or without DVT (310). The median age was 69 (55–80, 25th–75th percentiles). Patients with PE-associated DVT had more severe forms of PE (p < 0.0001) and, when DVT was present, proximal location was significantly correlated to PE severity (p < 0.01). However, no difference in all-cause mortality rate (hazard ratio (HR) 1.36 (CI 95% 0.69–2.92)), nor in the composite criterion of all-cause mortality and recurrence rate (HR 1.56 (CI 95% 0.83–3.10)) was noted at 3 months of follow-up. Conclusion: In REMOTEV, coexisting DVT was associated with a higher severity of PE, with no impact on short-term prognosis.

show abstract

“…Nevertheless, the identification of other risk factors for venous thrombosis remains a major issue in the prevention of VTE and its recurrence, and they are key determinants for the treatment intensity and duration [3]. The REMOTEV registry study recently indicated that the risk of unprovoked VTE, the severity of pulmonary embolism, and the risk of VTE recurrence are associated with cardiovascular risk factors, especially age and diabetes [4]. Nonetheless, up to 50% of VTEs remain unprovoked and thus lead to long-term anticoagulation therapy which exposes patients to an increased hemorrhagic risk [5][6][7][8].…”

Section: Introductionmentioning

confidence: 99%

Oral Intake of EPA:DHA 6:1 by Middle-Aged Rats for One Week Improves Age-Related Endothelial Dysfunction in Both the Femoral Artery and Vein: Role of Cyclooxygenases

Gærtner

Auger

Farooq

et al. 2020

IJMS

View full text Add to dashboard Cite

In humans, aging is associated with endothelial dysfunction and an increased risk of venous thromboembolism. Although intake of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) at a ratio of 6:1 by old rats improved the endothelial dysfunction in arteries, the impact on veins remains unclear. Eight-month-old male Wistar rats were either untreated or orally administered corn oil, EPA:DHA 1:1, or EPA:DHA 6:1 (500 mg/kg/d) for seven days. Vascular reactivity was studied by myography. In middle-aged femoral artery rings, acetylcholine caused a partial relaxation at low concentrations and a contractile response at high concentrations, whereas in the old femoral vein only a partial relaxation was observed. The EPA:DHA 6:1 treatment blunted the contractile response to acetylcholine in the middle-aged femoral artery and both EPA:DHA 6:1 and 1:1 increased the relaxation to acetylcholine in the old femoral vein. No such effects were observed with corn oil. Both the non-selective cyclooxygenase inhibitor indomethacin and the COX-1 inhibitor SC-560 increased the relaxation to acetylcholine in the middle-aged femoral artery whereas the COX-2 inhibitor NS-398 increased that in the middle-aged femoral vein. In conclusion, our results indicate that aging is associated with an endothelial dysfunction in the femoral artery and vein, which can be improved by EPA:DHA 6:1 treatment—most likely via a cyclooxygenase-dependent mechanism.

show abstract

Increased risk and severity of unprovoked venous thromboembolism with clustering cardiovascular risk factors for atherosclerosis: Results of the REMOTEV registry

Cited by 14 publications

References 39 publications

Editor's Choice – European Society for Vascular Surgery (ESVS) 2021 Clinical Practice Guidelines on the Management of Venous Thrombosis

Editor's Choice – European Society for Vascular Surgery (ESVS) 2021 Clinical Practice Guidelines on the Management of Venous Thrombosis

Pulmonary Embolism and Coexisting Deep Vein Thrombosis: A Detrimental Association?

Oral Intake of EPA:DHA 6:1 by Middle-Aged Rats for One Week Improves Age-Related Endothelial Dysfunction in Both the Femoral Artery and Vein: Role of Cyclooxygenases

Contact Info

Product

Resources

About